Longevity Technology: Equity investment in MDI Therapeutics by Juvenescence will develop novel serpin-based therapies
Share
Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
Serine proteases have been described as the “workhorses of the human body.”
But serpins have historically been a challenging target for pharmaceutical development. MDI has shown that they can successfully use their proprietary high throughput screening platform to find novel drug candidates. Their lead program, a first-in-class orally available Plasminogen Activator Inhibitor (PAI-1) inhibitor, has demonstrated efficacy in multiple preclinical models of fibrosis and thrombosis, as well as a promising pharmacokinetic and safety profile. Juvenescence experience in bringing therapies to market, in addition to its equity investment, is seen as a strategic advantage for MDI.
Read the full Longevity Technology article here.
Serine proteases have been described as the “workhorses of the human body.”
But serpins have historically been a challenging target for pharmaceutical development. MDI has shown that they can successfully use their proprietary high throughput screening platform to find novel drug candidates. Their lead program, a first-in-class orally available Plasminogen Activator Inhibitor (PAI-1) inhibitor, has demonstrated efficacy in multiple preclinical models of fibrosis and thrombosis, as well as a promising pharmacokinetic and safety profile. Juvenescence experience in bringing therapies to market, in addition to its equity investment, is seen as a strategic advantage for MDI.
Read the full Longevity Technology article here.